Good morning, everyone, and how are you today? We are just fine, thank you, despite another steamy day unfolding here on the Pharmalot campus, where the short people and the official mascots are all sleeping in. As for us, we are quaffing cups of stimulation, since the neurons can use a little help. Feel free to join us. And of course, here are some tidbits to enjoy, as well. Have a lovely day and do keep in touch …
The Irish Pharmaceutical Healthcare Association acknowledged it would have been better if more Irish doctors consented to being named as the recipients of payments from drug makers, the Irish Medical Times writes. The value of payments to health care providers and organizations was made public for the first time in June as part of a voluntary Europe-wide initiative, but only 55 percent of Irish doctors consented to being named.
Vertex Pharmaceuticals is ending a late-stage study testing a two-drug combination treatment on a small group of cystic fibrosis patients after an independent board concluded the therapy did not provide any benefit, the Boston Globe reports. The company had warned the trial might not prove effective. However, one Wall Street analyst noted this subgroup of patients is the primary untapped opportunity in cystic fibrosis that remains for Vertex.
About the Author Reprints
